banner about

An Emerging Vaccination Technology Company

CyTuVax is a young, clinical stage vaccine company, developing solutions to which there is a high medical need. Our interdisciplinary team collaborates with top European research institutions to explore the wide applicability of our technology to develop and enhance the effectiveness of vaccines.

Our adjuvant technology induces powerful immune responses, both humoral and cellular, and can be applied in prophylactic and therapeutic vaccine concepts. The powerful adjuvant increases immune responses to higher levels, widely improves the quality of standard vaccines, and decreases the number of vaccine injections.

Our Mission

 CyTuVax uses its adjuvant technology to develop both: prophylactic vaccines against viral & bacterial pathogens, and therapeutic vaccines against cancer. That is our mission, for which there is a high medical need. The patient is at the core in our vaccine development for which we apply our powerful adjuvant platform technology.

Latest news

showCyTuVax is currently testing its vaccine technology in a clinical Phase 2 study of a vaccine for hepatitis B non-responders

Where we are

About us

CyTuVax B.V.
Oxfordlaan 55
6229 EV Maastricht
The Netherlands

Contact us by email